CDK4 and breast carcinoma: In our extended experiment, we found that high level of COL11A1 contributed to reduced sensitivity of CDK4/6 inhibitors in ER+ breast cancer cells, suggesting inhibition of COL11A1 may enhance the efficacy of palbociclib, abemaciclib and ribociclib.